Overview
ExeVir is a clinical stage company that develops antibody therapies using a modular platform technology based on single domain antibody fragments (VHH). The platform creates therapeutic compounds capable of binding multiple epitopes on viral particles, designed to address emerging infectious disease variants. The company focuses initially on COVID-19 and dengue to help vulnerable patients including the immunocompromised.
Leadership & org chart
Alumni 1 went on to found or lead
Caroline SagaertHead of Operations→Founder and Owner at CAGISA Consulting
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.